From the observation of several different IRD in our clinical practice, we focused on those patients with a confirmed known pathogenic mutation, and a possible novel one in the PRPH2 gene, detected by a next generation sequencing (NGS) large genetic panel for MD, cone-rod dystrophy (CRD), and RP cases. This evidence concerns the gene PRPH2 and cone-rod dystrophy.